Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Dec 9;7(1):73.
doi: 10.1186/s40658-020-00339-2.

Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Affiliations

Kidney dosimetry in 777 patients during 177Lu-DOTATATE therapy: aspects on extrapolations and measurement time points

Mattias Sandström et al. EJNMMI Phys. .

Abstract

Purpose: Fractionated peptide receptor radionuclide therapy (PRRT) with 177Lu-DOTATATE is increasingly applied as an effective treatment for patients with disseminated neuroendocrine tumors. In parallel to dose planning before external beam radiation therapy, dosimetry is also needed to optimize PRRT to the individual patient. Accordingly, absorbed doses to organs at risk need to be calculated during PRRT, based on serial measurements of radioactivity distribution utilizing SPECT/CT. The dosimetry should be based on as few measurements as possible, while still retaining reliable results. The main aim of the present work was to calculate the fractional contribution of the extrapolations of the curve fits for the absorbed dose calculations to the kidneys. The secondary aim was to study agreement between absorbed dose (AD) and the effective half-life (teff) for the kidneys, estimated by means of measurements at one or two time points, in comparison to our current method employing three time points.

Methods: In 777 patients with disseminated neuroendocrine tumors undergoing PRRT, SPECT/CT over the abdomen was acquired at 1, 4, and 7 days after 177Lu-DOTATATE infusion. The absorbed dose to the kidneys was calculated from SPECT/CT radioactivity distribution data, and the teff and fractional contributions of the extrapolations were estimated, utilizing data from one, two, and three time points, respectively.

Results: The fractional contributions from extrapolations before day 1 measurement and after day 7 measurement were approximately 26% and 11%, respectively. The mean differences in absorbed dose, based on one, two, and three time points were small, but with high method dependence for individual patients. The differences in estimated teff were small when it was based on measurements at days 1 and 7, but high for days 1 and 4 time points.

Conclusion: When assessing simplifications of methods for calculation of the absorbed dose to the kidneys, it was of the uttermost importance to incorporate the fractional contribution for the extrapolations included in the reference method. Measurements at an early and a late time point were found most important. An intermediate measurement contributes with an idea of the goodness of the fit.

Keywords: 177Lu-DOTATATE; Dosimetry; Extrapolation; Kidney; Neuroendocrine tumors; Simplifications.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Examples of fractional contributions on a typical curve for the kidney for a (fc0-24) the extrapolated portion of the curve from time = 0 to the measurement at day 1, b (fc168-∞) the portion of the curve after the day 7 measurement (to infinity), c (fc0-24 + 168-∞) the sum of fc0-24 and fc168-∞, d (fc96-∞) the portion of the curve after the day 4 measurement (to infinity), e (fc0-24 + 96-∞) the sum of fc0-24 and fc96-∞, and (fc0-8) the fractional contribution of the first 8 h
Fig. 2
Fig. 2
Fractional contribution of absorbed dose calculations for the left kidney to the total number of decays
Fig. 3
Fig. 3
Histograms of the absorbed doses using our standard method AD147, based on SPECT/CT measurements at days 1, 4, and 7, for the a left kidney and b right kidney
Fig. 4
Fig. 4
Bland-Altman plots of the percent difference versus the mean for the left kidneys in our standard method AD147 versus the simplified methods a AD14, b AD17, c AD4/52, and d AD4/H
Fig. 5
Fig. 5
Bland-Altman plots of the percent difference versus the mean for the left kidneys in the simplified method AD14 versus the single time point methods a AD4/52 and b AD4/H
Fig. 6
Fig. 6
Histograms of the effective half-lives in the absorbed dose calculation using our standard method (AD147) for the a left kidney and b right kidney and using the simplified method AD14 for the c left kidney and d right kidney
Fig. 7
Fig. 7
Bland-Altman plot of the effective half-life (teff) for the reference method using data from 1, 4, and 7 days (teff147) versus the simplified methods a using data from 1 and 4 days (teff14) and b using data from 1 and 7 days (teff17)

Similar articles

Cited by

References

    1. Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol. 2011;29:2416–2423. doi: 10.1200/JCO.2010.33.7873. - DOI - PubMed
    1. Bodei L, Cremonesi M, Grana CM, Fazio N, Iodice S, Baio SM, et al. Peptide receptor radionuclide therapy with (1)Lu-DOTATATE: the IEO phase I-II study. Eur J Nucl Med Mol Imaging. 2011;38:2125–2135. doi: 10.1007/s00259-011-1902-1. - DOI - PubMed
    1. Gabriel M, Andergassen U, Putzer D, Kroiss A, Waitz D, Von Guggenberg E, et al. Individualized peptide-related-radionuclide-therapy concept using different radiolabelled somatostatin analogs in advanced cancer patients. Q J Nucl Med Mol Imaging. 2010;54:92–99. - PubMed
    1. Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol. 2008;26:2124–2130. doi: 10.1200/JCO.2007.15.2553. - DOI - PubMed
    1. Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al. Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol. 2005;23:2754–2762. doi: 10.1200/JCO.2005.08.066. - DOI - PubMed

LinkOut - more resources